-
Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial
•
China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green light from the US Food and Drug Administration (FDA) to initiate a Phase II clinical study for its Category 1 chemical drug, GS1-144, in treating menopausal vasomotor symptoms (VMS). Understanding Menopausal Vasomotor Symptoms and the…
-
Changchun High & New Technology Industries Receives NMPA Approval for Long-Acting Somatropin
•
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading China-based company, has announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its polyethylene glycol recombinant human somatropin, a long-acting somatropin, for the treatment of idiopathic short stature (ISS). Understanding Idiopathic…
-
Changchun High & New Technology Industries Receives FDA Tacit Approval for GenSci122 Clinical Study
•
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company, has announced that it has received tacit approval from the US Food and Drug Administration (FDA) to commence a clinical study for its drug candidate, GenSci122, in patients with advanced solid tumors. GenSci122 is a small…
-
Changchun High & New Technology Industries Receives FDA Approval for GenSci098 Clinical Trial in Thyroid Eye Disease
•
Changchun High & New Technology Industries (Group) Inc., a Chinese corporation listed on the Shenzhen Stock Exchange (SHE: 000661), has received tacit approval from the US Food and Drug Administration (FDA) to initiate a clinical study for its Category 1 biologic product, GenSci098. This humanized anti-TSHR antagonistic monoclonal antibody (mAb)…
-
Changchun High & New Technology Secures NMPA Approval for Turner Syndrome Treatment
•
CHANGCHUN—Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading biopharmaceutical company in China, has announced that it has received additional indication approval from the National Medical Products Administration (NMPA) for its polyethylene glycol recombinant human somatropin. This long-acting somatropin is now approved for use in growth disorders…
-
Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial
•
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 biologic product, jinnamab. This marks a significant milestone for the…
-
Changchun High & New Technology Industries to Launch GenSci125 Phase I Trial in US
•
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company, has announced the upcoming initiation of a Phase I clinical study for its investigational drug GenSci125 in the United States. The study is designed to evaluate the drug’s efficacy in luteal supplementation or replacement for…
-
Changchun High & New Technology to Transfer 7.42% Stake to Ex-Wife in Divorce Settlement
•
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has announced plans to transfer 30,014,100 shares, representing a 7.42% stake, to Wang Simian, the ex-wife of company shareholder Jin Lei and founder of subsidiary Changchun GeneScience Pharmaceutical Co., Ltd., as part of their divorce agreement. Based on the estimated…
